PUBLIC COMPANY
save$BMYBRISTOL MYERS SQUIBB CO
$BMY61.35-2.51%Princeton, NJ, USupdated 1d ago
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multip read more
…
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval166 co-mentions · 83 sources
- drugOPDIVO166 co-mentions · 83 sources
- drugOPDIVO QVANTIG166 co-mentions · 83 sources
- drugnivolumab166 co-mentions · 83 sources
- company$CELG-RIBRISTOL MYERS SQUIBB CO84 co-mentions · 84 sources
- tagDrug Shortage1 co-mentions · 1 sources
- drugazacitidine1 co-mentions · 1 sources
- drugOnureg1 co-mentions · 1 sources
pipeline
3
marketed
0
phase 3
0
catalysts ytd
6
approvals ytd
2
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Unknown
drug
INREBIC
1 INDICATIONS AND USAGE INREBIC ® is indicated for the tr…
Tyrosine-protein kinase JAK2Receptor-type tyrosine-protein kinase FLT3
drugOPDIVO
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1
drugOPDIVO QVANTIG
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
🐶 Hiring Signal
Where BRISTOL MYERS SQUIBB CO is staffing up — a leading indicator of pipeline and commercial priorities.
News
- CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questionsAt the Clinical Trials on Alzheimer’s Disease Conference, BMS finally revealed early data for its Alzheimer’s disease psychosis trials of KarXT, marketed as Cobenfy in schizophrenia.biospace · 6h ago
- CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBiogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…biospace · 6h ago
- Pfizer leaps into ‘in vivo’ CAR-T with latest China dealThe potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.biopharma_dive · 6h ago
- Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsMerck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.biospace · 7h ago
- Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B dealThe Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.biospace · 8h ago
- Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safetySummit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.biospace · 10h ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 12h ago
- AI drugmaker Isomorphic restocks with $5B fundraiseEven as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.biopharma_dive · 1d ago
- AstraZeneca, Calidi, Tempest make significant workforce cutsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapyAt the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.biospace · 1d ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that